Section Editors

Maurice Pérol - Head of Thoracic Oncology, Medical Oncology Department of Léon Bérard Cancer Center in Lyon.

Maurice Pérol

Head of Thoracic Oncology, Medical Oncology Department of Léon Bérard Cancer Center in Lyon.

Maurice Pérol, M.D., was Associate Professor of Pneumology and Head of the Department of Thoracic Oncology at the Croix-Rousse University Hospital in Lyon, France from 1993 until 2011. He joined in 2011 the Medical Oncology Department of Léon Bérard Cancer Center in Lyon, in which he is responsible for Thoracic Oncology.
His fields of scientific work include clinical phase I, II and III studies in lung cancer, especially in advanced non-small cell lung cancer; this work involves being a principal investigator or key investigator in several French or international cooperative studies. Of note, he was the principal investigator of the IFCT-GFPC 0502 maintenance French study which involves more than 70 centers in France and the co-principal investigator of the international REVEL phase III study assessing ramucirumab in second-line treatment of NSCLC.
He is an active member of many scientific societies, including ASCO, IASLC and ESMO, and collaborative groups. He was the Chairman of the Groupe Français de Pneumo-Cancérologie (GFPC) from 1998 to 2002 and Executive Board member of the French Cooperative Group of Thoracic Oncology "Intergroupe Francophone de Cancérologie Thoracique" (IFCT) from 1999 to 2003; he is member of the IFCT Scientific Board since 2003. He is the author or co-author of more than 140 publications in peer-reviewed journals.

Latest Articles

Latest Videos

Video List based on Category on Node Page

Latest Videos

Part 2 of 2 - Dr David Heigener discusses the large number of patients that can’t receive targeted therapy or checkpoint inhibitors, and other unmet needs in non-small cell lung cancer (NSCLC). He also gives us his thoughts on liquid biopsy and its use in NSCLC. Filmed at The American Society of Clinical Oncology (ASCO) meeting, 2017
Part 1 of 2 – The first part of our interview with Dr David Heigener highlights the lack of data on combination therapies for EGFR-positive non-small cell lung cancer and the issues with synergistic toxicity. Filmed at The American Society of Clinical Oncology (ASCO) meeting, 2017
Part 2 of 2 - Dr Maurice Pérol talks to us about the recent IFCT-GFPC 0502-Eco phase III study in optimization of maintenance therapy in non-small cell lung cancer, by tailoring the treatment according to the response from induction chemotherapy. Filmed at the American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, US, June 2017